Related Experiment Videos
Kynurenine pathway abnormalities in Parkinson's disease
T Ogawa1, W R Matson, M F Beal
1Brain Tissue Resource Center, McLean Hospital, Belmont, MA 02178.
Neurology
|September 1, 1992
Summary
3-O-methyldopa (3OMD) is a reliable biomarker for L-dopa therapy effectiveness in Parkinson's disease (PD) patients. Tryptophan (TRP) metabolite changes suggest mitochondrial complex I defects in PD brains.
Area of Science:
- Neuroscience
- Biochemistry
- Metabolomics
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopamine deficiency.
- L-dopa therapy is a primary treatment, but its efficacy and metabolic impact require further understanding.
- Alterations in neurotransmitter and tryptophan metabolism may offer insights into PD pathophysiology.
Purpose of the Study:
- To quantify key metabolites of tyrosine and tryptophan in specific brain regions of PD patients.
- To evaluate the utility of 3-O-methyldopa (3OMD) as a biomarker for L-dopa therapy.
- To investigate potential links between altered metabolite concentrations and mitochondrial dysfunction in PD.
Main Methods:
- Measurement of dopamine, 3OMD, serotonin, kynurenine (KYN), kynurenic acid (KYA), and 3-hydroxykynurenine (3OHKY) in human brain tissues (frontal cortex, putamen, substantia nigra).
- Comparison of metabolite levels between control subjects, PD patients without L-dopa therapy (PD[-]), and PD patients with L-dopa therapy (PD[+]).
- Analysis of tryptophan metabolite ratios to assess pathway integrity.
Main Results:
- Dopamine levels were decreased in PD tissues irrespective of L-dopa treatment.
- 3OMD concentrations were significantly elevated in L-dopa treated PD patients (PD[+]) compared to controls and PD[-] patients, indicating its potential as a therapy marker.
- Serotonin, KYN, and KYA levels were reduced in PD groups, while 3OHKY levels were increased, particularly in PD[+] patients.
- The kynurenine pathway alterations suggest a potential defect in mitochondrial NADH:ubiquinone oxidoreductase (complex I) in PD.
Conclusions:
- 3-O-methyldopa (3OMD) serves as a reliable indicator of L-dopa treatment in Parkinson's disease.
- Observed changes in tryptophan metabolites (KYN, KYA, 3OHKY) support the hypothesis of mitochondrial complex I dysfunction in PD.
- Metabolomic profiling provides valuable insights into the biochemical alterations underlying Parkinson's disease and its treatment response.